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Cannabis has long been known to produce cognitive and emotional effects. Research has
shown that cannabinoid drugs produce these effects by driving the brain’s endogenous
cannabinoid system and that this system plays a modulatory role in many cognitive and
emotional processes.This review focuses on the effects of endocannabinoid system mod-
ulation in animal models of cognition (learning and memory) and emotion (anxiety and
depression). We review studies in which natural or synthetic cannabinoid agonists were
administered to directly stimulate cannabinoid receptors or, conversely, where cannabinoid
antagonists were administered to inhibit the activity of cannabinoid receptors. In addition,
studies are reviewed that involved genetic disruption of cannabinoid receptors or genetic or
pharmacological manipulation of the endocannabinoid-degrading enzyme, fatty acid amide
hydrolase (FAAH). Endocannabinoids affect the function ofmany neurotransmitter systems,
some of which play opposing roles. The diversity of cannabinoid roles and the complexity
of task-dependent activation of neuronal circuits may lead to the effects of endocannabi-
noid system modulation being strongly dependent on environmental conditions. Recent
ﬁndings are reviewed that raise the possibility that endocannabinoid signaling may change
the impact of environmental inﬂuences on emotional and cognitive behavior rather than
selectively affecting any speciﬁc behavior.
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Cannabis has been used by humans for millennia and has long
been known to produce cognitive and emotional effects. Research
over the past two decades has shown that cannabinoid drugs pro-
duce these effects by driving the brain’s endogenous cannabinoid
system, and that this system plays a modulatory role in many
cognitive and emotional processes. This review will focus on the
effects of endocannabinoid system modulation in animal models
of cognition (learning and memory) and emotion (anxiety and
depression).
This research has been facilitated by the availability of pharma-
cological tools that are used in four general ways:
(1) An exogenous cannabinoid agonist can be administered
to directly stimulate cannabinoid receptors. Administering
cannabinoid receptor agonists such as Δ9-THC (the main
active constituent of cannabis) or WIN55212 (a synthetic
agonist) can provide information about the effects of illicit
cannabinoid use and also about the potential therapeutic or
adverse effects of cannabinoid-related medications. Cannabi-
noid substances that occur endogenously, such as anan-
damide,can alsobe synthesized andadministered exogenously
to gain insight into their function.
(2) A cannabinoid receptor antagonist can be administered along
with another treatment to determine whether effects of the
treatment depend on its actions at cannabinoid receptors.
For example, if blocking cannabinoid CB1 receptors with an
antagonist such as rimonabant prevents the treatment from
having a certain effect, that effect of the treatment is said to
be mediated by CB1 receptors.
(3) Ongoing endocannabinoid signaling can be blocked by
administering a cannabinoid receptor antagonist alone.When
endocannabinoid signaling is blocked, behaviors that are
modulated by this signaling should increases or decrease,
depending on whether the modulation is negative or positive.
This approach assumes that the antagonist blocks endoge-
nously released endocannabinoids, but does not otherwise
affect signaling. Unfortunately, the antagonists that have been
used most frequently for this purpose (rimonabant and
AM251) also function as inverse agonists and may affect
neuronal functions even in the absence of the release of
endocannabinoid agonists.
(4) Endocannabinoid signaling canbe enhancedby administering
an enzyme inhibitor that prevents the breakdown of endo-
cannabinoids that have been released. Endocannabinoids are
synthesized “on demand” when synaptic neurotransmission
surpasses a certain threshold. Treatments that prevent the
breakdown of endocannabinoids should mainly affect cells
in the immediate areas where an endocannabinoid is being
released. In contrast, exogenous agonists affect synapses wher-
ever the receptors are expressed. Thus, treatments that prevent
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endocannabinoid breakdown should magnify the ongoing
effects of endocannabinoids and might provide better insight
into normal function. Anandamide, the most frequently stud-
ied endocannabinoid, is degraded by the enzyme fatty acid
amid hydrolase (FAAH). Inhibitors of FAAH ﬁrst became
available about 7 years ago (e.g., Tarzia et al., 2003; Mor
et al., 2004), and there is now a large amount of information
concerning the effects of FAAH inhibitors on cognitive and
emotional behavior. Inhibitors of the degradation of 2-AG,
the other major endocannabinoid that has been identiﬁed,
have also been recently developed (e.g., Long et al., 2009),
but information on their cognitive or emotional impact is too
scarce to be reviewed at this time.
In addition to these four pharmacological approaches, the role
of endocannabinoids in cognitive and emotional processes can
be investigated with genetically modiﬁed strains of rodents. This
has been accomplished in two general ways: deleting a speciﬁc
cannabinoid receptor subtype (i.e., CB1), which excludes cannabi-
noid signaling; and deleting a metabolizing enzyme (i.e., FAAH),
which enhances endogenous endocannabinoid signaling.
Each of these pharmacological and genetic approaches has
advantages and disadvantages. For example, manipulating FAAH
affects not only endocannabinoids but related fatty acids that
bind at non-cannabinoid sites, such as peroxisome proliferator-
activated receptors and transient receptor-potential vanilloid
receptors. When a receptor or enzyme is genetically deleted, other
mechanisms may be affected by their absence. Therefore, the
best understanding is gained through convergence, comparing the
results obtained with different approaches.
EFFECTS OF ENDOCANNABINOID SYSTEM MODULATION ON
LEARNING AND MEMORY
The memory-impairing effects of marijuana in humans have been
widely recognized since at least the 1970s (Tart, 1970). Interest
in the role played by endocannabinoids in cognitive processes
has been stimulated by evidence that CB1 receptors are highly
expressed (Herkenham et al., 1991) – and endocannabinoids
(anandamide and 2-AG) occur in high concentrations (Di Marzo
et al., 2000) – in the hippocampus, a brain area that plays a criti-
cal role in learning and memory. Animal models have been used
extensively to assess the effects of cannabinoid manipulations on
various stages of learning andmemory, including acquisition, con-
solidation, and retrieval (Riedel and Davies, 2005; Varvel et al.,
2009). Most of these studies have involved spatial learning. In gen-
eral, the ﬁndings are that exogenous and endogenous cannabinoid
agonists impair working memory and the acquisition of long-
term memory, while cannabinoid antagonists/inverse agonists or
genetic deletion of cannabinoid receptors are sometimes found to
enhance learning and memory.
Endocannabinoid signaling can affect many behavioral and
physiological processes, including locomotion, feeding, anxiety,
reward, and nociception. Therefore, to conﬁdently attribute the
effects of cannabinoid manipulations to learning and memory
processes per se, as opposed to motivational, emotional, or motor
processes, it is important to consider complementary models. For
example, some memory models involve aversive motivation (e.g.,
escape from a water-ﬁlled pool), while others involve appetitive
motivation (e.g., food-reinforced behavior in delayed matching
tasks); ﬁnding similar effects of a drug in both aversive and appet-
itive models would suggest an effect on memory rather than
motivation. It can also be informative to test the effects of a treat-
ment in both a memory model and a more general, non-cognitive
behavioral assay, such as spontaneous locomotor activity in an
open ﬁeld. In the following sections, we will consider the ﬁndings
obtainedwith speciﬁcmodels of long-termmemory (see Effects of
Endocannabinoid System Modulation on Learning and Memory)
and working memory (see Working Memory).
EFFECTS OF CANNABINOID CB1 RECEPTOR AGONISTS AND
ANTAGONISTS ON MEMORY ACQUISITION AND LONG-TERM MEMORY
Water maze
Much of the evidence that activating cannabinoid receptors can
impair learning comes from studies using water maze proce-
dures, which focus on spatial memory. In these tests the animals
are trained to ﬁnd a submerged platform in a tank ﬁlled with
opaque water. Memory acquisition becomes evident over trials as
successive reductions in the path length or the latency to reach
the platform. In mice, acute systemic administration of Δ9-THC
(8mg/kg, IP) before the training session disrupts acquisition in
the water maze test without affecting locomotion; this effect is pre-
vented by the CB1 antagonist/inverse agonist rimonabant (DaSilva
and Takahashi, 2002). Deﬁcits in place-learning have also been
reported in rats treated repeatedly with Δ9-THC (Moore et al.,
2010) or acutely with Δ8-THC (Diana et al., 2003) or synthetic
CB1 agonists such asHU-210 (Ferrari et al., 1999), but not with the
synthetic agonist nabilone (Diana et al., 2003). However, in these
experiments, the effects of CB1-receptor blockade were not tested.
Another synthetic cannabinoid,WIN55212-2 (1 and 3mg/kg), has
been found to impair acquisition in the water maze, but his effect
was not blocked by CB1 antagonists, suggesting WIN55212-2 may
impair learning by more than one mechanism (Robinson et al.,
2010).
Water maze procedures have also been used to study the effects
of Δ9-THC on memory retrieval. For this purpose, rats that have
already reached a criterion level of performance in the task are
injected with the drug prior to a test session. Two laboratories
have reported that – at doses known to impair memory acquisi-
tion –Δ9-THCdid not impairmemory retrieval in thewatermaze
(Mishima et al., 2001;Varvel et al., 2001, 2007). These ﬁndings sug-
gest that, once established, reference memory is not susceptible to
modulation by cannabinoid compounds.
Contextual fear conditioning
CB1 agonists can also impair acquisition in another model of spa-
tial memory, contextual fear conditioning. In this test, rodents are
brieﬂy exposed to footshock in a distinctive context, then tested
by re-exposing them to the context. Immobility (freezing) dur-
ing the test provides a measure of memory. The synthetic CB1
agonist WIN55212-2 (2.5 and 5.0mg/kg), given 30min before the
conditioning phase, impaired acquisition of contextual fear con-
ditioning, but not conditioning to a discrete auditory cue (tone),
which unlike contextual conditioning is believed to be indepen-
dent of hippocampal function (Pamplona and Takahashi, 2006).
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This ﬁnding is consistent with an impairment of hippocampal
functioning, since the hippocampus mediates acquisition of fear
conditioning involving contextual cues but not discrete cues
(Phillips and LeDoux, 1992). Rimonabant (1mg/kg) blocked the
impairing effects of WIN55212-2, demonstrating the involvement
of CB1 receptors (Pamplona and Takahashi, 2006). Sink et al.
(2010) showed that administration of CB1 inverse agonists dur-
ing the acquisition phase improves the retention of the contextual
fear, consistent with endogenous cannabinoids having a negative
modulatory effect on memory acquisition.
Object recognition and social recognition
In a typical object recognition task, animals are exposed to an
object during one session,and then exposed to the sameobject plus
a novel object in a subsequent test session. The relative amount
of time spent exploring the novel object provides an index of
memory. Systemic or intra-hippocampal administration of Δ9-
THC or WIN55212-2, either acute or repeated, impaired object
recognition in rats (Barna et al., 2007; Quinn et al., 2008; Schnei-
der et al., 2008). This impairment is associated with differential
expression of proteins in the hippocampus (Quinn et al., 2008).
However, in another study acute systemic administration of Δ9-
THC before the task failed to affect object recognition in adult rats
(Ciccocioppo et al., 2002). Enhanced memory performance was
observed in CB1-knockout in this task (Maccarrone et al., 2002).
The roles of hippocampal functioning and spatial learning in
the conventional object recognition procedure are still controver-
sial (Ainge et al., 2006; Heuer and Bachevalier, 2011). It is possible
to modify the procedure to focus on spatial memory by present-
ing objects during the exposure phase, then presenting the same
objects during the test but with one placed in a different posi-
tion. Suenaga and Ichitani (2008) found that microinjection of
WIN55212-2 (1–2μg/side in the hippocampus 10min before the
initial exposure to the objects) did not affect memory in the con-
ventional procedure but impaired in a CB1 dependent fashion the
ability to recognize a new spatial conﬁguration of objects.
The social recognition test is similar to the object recognition
test but uses conspeciﬁcs instead of objects as the stimuli. Using
long delays (15–30min) it has been shown that the administration
of WIN55212-2 impairs the performance of rats in a CB1 depen-
dent fashion (Schneider and Koch, 2002; Schneider et al., 2008).
Rimonabant has been found to enhance recognition memory in
this test (Terranova et al., 1996).
Radial maze
The effects of CB1 compounds on the acquisition and recall of
spatial memory in rodents have also been studied using a mod-
iﬁed version of the radial maze test. In the conventional version
of the test a food pellet is available at the end of each of the eight
arms of the maze, and re-entering the same arm more than once
indicates a working-memory error. In the modiﬁed version, to
manipulate the mnemonic demand of the test, the rat is removed
from the maze after it enters the seventh arm of the maze, and then
it is placed back in the maze after a delay (Lichtman, 2000). With
long delays, this test provides a test of long-term memory. Rimon-
abant (3mg/kg), given to rats before the ﬁrst placement in the
maze, reduces the number of errors after a 6-h delay (Lichtman,
2000). Rimonabant had no effect when administered immedi-
ately after the ﬁrst placement (Wise et al., 2007) or before the
test placement (Lichtman, 2000), suggesting rimonabant enhances
memory acquisition but not consolidation or retrieval. However,
in other studies, the facilitating effects of CB1 antagonism have
been observed not only for acquisition, but also for consolidation
(Wolff and Leander, 2003; Wise et al., 2008).
Passive avoidance
Data obtained with passive-avoidance procedures suggest a mod-
ulatory action of the endocannabinoids system on all phases of
memory. In a widely used, hippocampal-dependent version of this
test, rodents are allowed to explore a apparatus with two compart-
ments, one lighted and one dark (Isaacson and Wickelgren, 1962).
Entrance into the dark compartment is paired with a foot shock
during a training session, and increased latency to enter the dark
compartment during a subsequent test session is used as an index
of conditioning. Systemic injections of Δ9-THC or anandamide
or intra-hippocampal injections of WIN55212-2 impair memory
acquisition, consolidation, and recall in rats and mice (Castellano
et al., 1997; Mishima et al., 2001; Costanzi et al., 2004; Nasehi
et al., 2010). However it has been shown that the effects of anan-
damide on passive-avoidance performance can vary depending on
the strain of the animals and on the protocol used (e.g., whether
subjects are pre-exposed to the testing apparatus; Castellano et al.,
1999; Costanzi et al., 2004).
Caveats
Taken together, the ﬁndings with these various animal models of
long-termmemory suggest amodulatory role of the endocannabi-
noid system during the acquisition phase of a place memory (see
Table 1).Generally,CB agonists have been found to impair acquisi-
tion, and antagonismor deletion of CB receptors has been found to
enhance it. However, there are some caveats to this conclusion. For
example, neither the CB1 inverse agonist/antagonist rimonabant
at different doses (1, 3mg/kg) nor the genetic disruption of CB1
receptors facilitated acquisition in the water maze (DaSilva and
Takahashi, 2002; Varvel and Lichtman, 2002; Varvel et al., 2007).
Several reports have indicated that the effects of CB1 agonists are
not limited to acquisition in passive avoidance and delayed radial
maze procedures.
In some cases, discrepant results in models of memory may
be attributable to cannabinoid effects on other processes. For
example, Mikics et al. (2006) reported an enhancement of fear
conditioning, rather than an impairment, after administration of
WIN55212-2, and tests employing genetic disruption or pharma-
cological blockade of CB1 receptors indicated that this enhance-
ment of fear conditioning was due to actions of WIN55212-2 at
CB1 receptors. Although this ﬁnding is inconsistent with the more
common ﬁnding that CB1 activation impairs memory acquisition,
in this case it is possible thatWIN55212-2may have increased anx-
iety. It is possible that some of the effects of CB1 agonists on water
maze behavior are due to thigmotaxis, an anxiety-related tendency
to maintain close proximity to the wall of the maze. When Ache-
son et al. (2011) controlled for thigmotaxis, the impairing effects
of WIN55212-2 were no longer detectable.
Another issue to consider is that endocannabinoid receptors
localized in different brain structures may modulate distinct
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Table 1 | Summary of studies investigating the effects of cannabinoid receptor agonists, cannabinoid receptor antagonists, FAAH inhibitors, or
genetic deletion of cannabinoid receptors on learning and memory in rodents.
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Harloe et al. (2008) C57BL/6J Rimonabant 3mg/kg, IP Appetitive
Barnes maze
tasks
Extinction =
Harloe et al. (2008) C57BL/6J Rimonabant 3mg/kg, IP Aversive
Barnes maze
tasks
Extinction ↓
Pamplona andTakahashi
(2006)
Wistar rat AM404 10mg/kg,
IP
Contextual fear
conditioning
Extinction ↑
Pamplona andTakahashi
(2006)
Wistar rat WIN55,212-2 0.25mg/kg,
IP
Contextual fear
conditioning
Extinction ↑
Bitencourt et al. (2008) Wistar rats AM404 1.0μg/μL,
i.c.v.
Contextual fear
conditioning
Extinction ↑
Suzuki et al. (2004) C57BL/6 Rimonabant 1–3–
10mg/kg,
IP
Contextual fear
conditioning
Extinction ↓
Niyuhire et al. (2007) C57BL/6J Rimonabant 3mg/kg, IP Contextual fear
conditioning
Extinction ↓
Pamplona andTakahashi
(2006)
Wistar rat Rimonabant 1mg/kg, IP Contextual fear
conditioning
Extinction ↓
Ganon-Elazar and Akirav
(2009)
Sprague-Dawley
rats
WIN55,212-2 2.5μg/0.5μL,
IC
(basolateral
amygdala)
Contextual fear
conditioning
after stress
Extinction ↑
Mikics et al. (2006) CD1 mice WIN55,212-2 3mg/kg, IP Contextual fear
conditioning
Recall ↑
Mikics et al. (2006) CD1 mice AM251 3mg/kg, IP Contextual fear
conditioning
Recall ↓
Mikics et al. (2006) CB1 KO N/A N/A Contextual fear
conditioning
↓
Pamplona andTakahashi
(2006)
Wistar rats WIN55,212-2 2.5 and, IP
5.0mg/kg
Contextual fear
conditioning
Acquisition ↓
Sink et al. (2010) Sprague-Dawley
rats
AM251 4.0 or
8.0mg/kg,
IP
Contextual fear
conditioning
Acquisition ↑
Pamplona andTakahashi
(2006)
Wistar rats Rimonabant 1mg/kg, IP Contextual fear
conditioning
Acquisition =
Pamplona andTakahashi
(2006)
Wistar rats WIN55,212-2 2.5 and
5.0mg/kg,
IP
Cue fear
conditioning
Acquisition =
Marsicano et al. (2002) CB1 KO N/A N/A Cue fear
conditioning
Extinction ↓
Kamprath et al. (2006) CB1 KO N/A N/A Cue fear
conditioning
Extinction ↓
Wise et al. (2008) Sprague-Dawley
rats
CE 0.03, 0.1,
0.3, 1.0, and
3.0mg/kg,
IP
Delay radial
maze
Acquisition ↑
Wise et al. (2008) Sprague-Dawley
rats
CE 0.1mg/kg,
IP
Delay radial
maze
Consolidation ↑
Wise et al. (2008) Sprague-Dawley
rats
CE 0.1mg/kg,
IP
Delay radial
maze
Recall =
(Continued)
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Table 1 | Continued
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Nakamura et al. (1991) Wistar rats Δ 9-THC 1.25mg/kg,
IP
Delay radial
maze
Recall =
Lichtman (2000) Sprague-Dawley
rats
Rimonabant 3mg/kg, IP Delay radial
maze
Acquisition ↑
Wise et al. (2007) Sprague-Dawley
rats
Rimonabant 1mg/kg, IP Delay radial
maze
Acquisition ↑
Wise et al. (2007) Sprague-Dawley
rats
Rimonabant 1mg/kg, IP Delay radial
maze
Consolidation =
Wolff and Leander
(2003)
Sprague-Dawley
rats
Rimonabant 1mg/kg, IP Delay radial
maze
Consolidation ↑
Lichtman (2000) Sprague-Dawley
rats
Rimonabant 3mg/kg, IP Delay radial
maze
Recall =
Wise et al. (2007) Sprague-Dawley
rats
Rimonabant 1mg/kg, IP Delay radial
maze
Recall =
Hampson and
Deadwyler (2000)
Long–Evans rats WIN55,212-2 0.25–
0.75mg/kg,
IP
DNMTP Working-
memory
test
↓
Deadwyler et al. (2007) Long–Evans rats WIN55,212-2 0,35mg/kg,
IP
DNMTP Working-
memory
test
↓
Hampson and
Deadwyler (2000)
Long–Evans rats Δ 9-THC 0.5, 1.0, 1.5,
and
2.0mg/kg,
IP
DNMTP Working-
memory
test
↓
Heyser et al. (1993) Sprague-Dawley
rats
Cannabidiol 2mg/kg, IP DNMTP Working-
memory
test
↓
Heyser et al. (1993) Sprague-Dawley
rats
Δ 9-THC 2mg/kg, IP DNMTP Working-
memory
test
↓
Panlilio et al. (2011) Sprague-Dawley
and Long–Evans
hooded rats
Δ 9-THC 1–
5.6mg/kg,
IP
DNMTP Working-
memory
test
Mallet and Beninger
(1998)
Wistar rats Anandamide 2mg/kg, IP DNMTP Working-
memory
test
↓
Deadwyler et al. (2007) Long–Evans rats Rimonabant 2mg/kg, IP DNMTP Working-
memory
test
↑
Mallet and Beninger
(1998)
Wistar rats Rimonabant 2mg/kg, IP DNMTP Working-
memory
test
=
Chhatwal et al. (2005) Sprague-Dawley
rats
WIN
55,212-2
5mg/kg, IP Fear
potentiated
startle
response
Extinction =
Chhatwal et al. (2005) Sprague-Dawley
rats
AM404 10mg/kg,
IP
Fear
potentiated
startle
response
Extinction ↑
(Continued)
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Table 1 | Continued
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Chhatwal et al. (2005) Sprague-Dawley
rats
Rimonabant 1.5 and
5mg/kg, IP
Fear
potentiated
startle
response
Extinction ↓
Niyuhire et al. (2007) C57BL/6J Rimonabant 3mg/kg Food Self
administration
Extinction =
Hölter et al. (2005) CB1 KO N/A N/A Food Self
administration
Extinction =
Varvel et al. (2007) C57BL/6 mice OL-135 30mg/kg,
IP
Modiﬁed
water maze
Acquisition ↑
Varvel et al. (2001) C57BL/6 mice Δ 9-THC 3mg/kg, IP Modiﬁed
water maze
Recall ↓
Varvel et al. (2005b) C57BL/6 mice Δ 9-THC 10mg/kg,
IP
Modiﬁed
water maze
Recall ↓
Varvel et al. (2007) FAAH KO N/A N/A Modiﬁed
water maze
↑
Varvel et al. (2006) FAAH KO N/A N/A Modiﬁed
water maze
↑
Schneider et al. (2008) Sprague-Dawley
rats
WIN55,212-2 1.2mg/kg,
IP
Object
recognition
test
Acquisition ↓
Ciccocioppo et al.
(2002)
Wistar rats Δ 9-THC 2 or
5mg/kg, IP
Object
recognition
test
Acquisition =
Barna et al. (2007) Wistar rats WIN55,212-2 Osmotic
pump
0.13TBq/mmol,
IC (hip-
pocampus)
Object
recognition
test
Acquisition ↓
Quinn et al. (2008) Wistar rats Δ 9-THC 5mg/kg, IP Object
recognition
test
Acquisition ↓
Suenaga and Ichitani
(2008)
Wistar-Imamichi
rats
WIN55,212-2 1–2μg/side,
IC (hip-
pocampus)
Object
recognition
test
Acquisition =
Maccarrone et al.
(2002)
CB1 KO N/A N/A Object
recognition
test
↑
Costanzi et al. (2004) CD1 mice Anandamide 0.3 and
0.5mg/kg,
IP
Passive
avoidance
Consolidation ↓
Castellano et al. (1999) CD1 mice Anandamide 1.5, 3,
6mg/kg, IP
Passive
avoidance
Consolidation ↓
Nasehi et al. (2010) NMRI mice WIN55,212-2 0.25, 0.5,
and
1μg/mouse,
IC (hip-
pocampus)
Passive
avoidance
Recall ↓
Mazzola et al. (2009) Sprague-Dawley URB597 0.1–0.3–
1mg/kg,
IP
Passive
avoidance
Acquisition ↑
(Continued)
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Table 1 | Continued
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Mazzola et al. (2009) Sprague-Dawley WY14643 10 20
40mg/kg,
IP
Passive
avoidance
Acquisition ↑
Mazzola et al. (2009) Sprague-Dawley URB597 0.1–0.3–
1mg/kg,
IP
Passive
avoidance
Consolidation =
Mazzola et al. (2009) Sprague-Dawley URB597 0.1–0.3–
1mg/kg,
IP
Passive
avoidance
Recall =
Mishima et al. (2001) Wistar rats Δ 9-THC 10mg/kg,
IP
Passive
avoidance
Acquisition ↓
Murillo-Rodríguez et al.
(2001)
Wistar rats OEA 30mg/kg Passive
avoidance
Extinction ↑
Mishima et al. (2001) Wistar rats Δ 9-THC 6mg/kg, IP Passive
avoidance
Recall ↓
Campolongo et al.
(2009b)
Sprague-Dawley WIN55,212-2 50 ng, intra
BLA
Passive
avoidance
Recall ↑
Campolongo et al.
(2009b)
Sprague-Dawley AM251 0.28 ng, IC
(basolateral
amygdala)
Passive
avoidance
Recall ↓
Niyuhire et al. (2007) C57BL/6J Rimonabant 3mg/kg, IP Passive
avoidance
Extinction ↓
Suenaga and Ichitani
(2008)
Wistar–Imamichi
rats
WIN55,212-2 1–2μg/side,
IC (hip-
pocampus)
Place
recognition
test
Acquisition ↓
Inui et al. (2004) Wistar rats Δ 9-THC 6mg/kg, IP Radial maze Working-
memory
test
↓
Lichtman et al. (1995) Sprague-Dawley CP-55,940 0.13mg/kg,
IP
Radial maze Working-
memory
test
↓
Lichtman et al. (1995) Sprague-Dawley CP-55,940 8μg/rat, IC
(hippo)
Radial maze Working-
memory
test
↓
Lichtman et al. (1995) Sprague-Dawley WIN55,212-2 2.1 and
2.2mg/kg,
IP
Radial maze Working-
memory
test
↓
Lichtman et al. (1995) Sprague-Dawley Δ 9-THC 2.1 and
2.2mg/kg,
IP
Radial maze Working-
memory
test
↓
Lichtman and Martin
(1996)
Sprague-Dawley Δ 9-THC 3mg/kg, IP Radial maze Working-
memory
test
↓
Wise et al. (2009b) Sprague-Dawley
rats
CP-55,940 10μg/rat,
IC (hip-
pocampus)
Radial maze Working-
memory
test
↓
Wise et al. (2009b) Sprague-Dawley
rats
Δ 9-THC 5.6mg/kg,
IP
Radial maze Working-
memory
test
↓
Rubino et al. (2009) Sprague-Dawley
rats
Δ 9-THC 2.5 to
10mg/kg in
10 days, IP
Radial maze Working-
memory
test
↓
(Continued)
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Table 1 | Continued
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Egashira et al. (2002) Wistar rats Δ 9-THC 20μg/side,
IC (hip-
pocampus)
Radial maze Working-
memory
test
↓
Egashira et al. (2008) Wistar rats Δ 9-THC 6mg/kg, IP Radial maze Working-
memory
test
↓
Molina-Holgado et al.
(1993)
Wistar rats Δ 9-THC 5mg/kg,
PO
Radial maze Working-
memory
test
↓
Nakamura et al. (1991) Wistar rats Δ 9-THC 1.25mg/kg,
IP
Radial maze Working-
memory
test
↓
Rodrigues et al. (2011) Wistar rats Δ 9-THC 0.5μL, IC
(medial
prefrontal
cortex)
Radial maze Working-
memory
test
↓
Mishima et al. (2001) Δ 9-THC 4–6mg/kg,
IP
Radial maze Working-
memory
test
↓
Varvel et al. (2005b) C57BL/6 mice Δ 9-THC 10mg/kg T-maze Working-
memory
test
↓
Nava et al. (2001) Sprague-Dawley Δ 9-THC 2.5 and
5mg/kg, IP
T-maze Working-
memory
test
↓
Jentsch et al. (1998) Sprague-Dawley Δ 9-THC 5mg/kg, IP T-maze Working-
memory
test
↓
Varvel et al. (2007) C57BL/6 mice Δ 9-THC 0.1, 0.3, 1,
or
10mg/kg,
IP
Water maze Extinction =
Varvel et al. (2001) C57Bl/6 mice Δ 9-THC 3, 10, and
30mg/kg,
IP
Water maze Recall =
Varvel et al. (2007) C57BL/6J OL-135 30mg/kg,
IP
Water maze Extinction ↑
Robinson et al. (2010) Lister Hooded
rats
WIN55,212-2 1 and
3mg/kg, IP
Water maze Acquisition ↓
Moore et al. (2010) Sprague-Dawley
CD rats
Δ 9-THC 10mg/kg,
IP
Water maze Acquisition ↓
Diana et al. (2003) Sprague-Dawley
rats
Nabilone 0.1, 0.5,
and
1.0mg/kg,
IP
Water maze Acquisition =
Acheson et al. (2011) Sprague-Dawley
rats
WIN55,212-2 1mg/kg, IP Water maze Acquisition =
Diana et al. (2003) Sprague-Dawley
rats
Δ 8-THC 5mg/kg, IP Water maze Acquisition ↓
DaSilva andTakahashi
(2002)
Swiss albino Δ 9-THC 8mg/kg, IP Water maze Acquisition ↓
(Continued)
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Table 1 | Continued
Authors Animals Drug Doses and
route
Test Administered
before
Effects on
memory
Ferrari et al. (1999) Wistar
Hannover rat
HU-210 50 and
100μg/kg,
IP
Water maze Acquisition ↓
Mishima et al. (2001) Wistar rats Δ 9-THC 6 and
10mg/kg,
IP
Water maze Recall =
Varvel et al. (2007) C57BL/6 mice Rimonabant 3mg/kg, IP Water maze Acquisition =
Varvel et al. (2007) C57BL/6 mice Rimonabant 3mg/kg, IP Water maze Acquisition =
Varvel et al. (2005a) C57BL/6J Rimonabant 3mg/kg, IP Water maze Extinction ↓
DaSilva andTakahashi
(2002)
Swiss albino
mice
Rimonabant 1mg/kg, IP Water maze Acquisition =
Varvel et al. (2005a) CB1 KO N/A N/A Water maze (Extinction) ↓
Varvel et al. (2007) FAAH KO N/A N/A Water maze (Extinction) ↑
Varvel et al. (2006) FAAH KO N/A N/A Water maze Working-
memory
test
↑
Varvel et al. (2007) FAAH KO N/A N/A Water maze ↑
Varvel et al. (2006) FAAH KO N/A N/A Water maze
reversal
learning
↑
Varvel and Lichtman
(2002)
CB1 KO N/A N/A Water maze =
DNMTP, delayed non-matching to position; KO, knockout; WT, wild type. For effects on memory, ↓ indicates impairment; ↑ indicates enhancement;= indicates no
effect.
memory process. This may explain cases where microinfusion
of cannabinoid compounds into speciﬁc areas produces effects
opposite to those usually seen with systemic administration. For
example, Campolongo et al. (2009b) found that micro-injections
of WIN55212-2 into the basolateral amygdala enhanced memory
retention and the CB1 antagonist AM251 caused impairments in
a passive-avoidance test.
WORKING MEMORY
Working memory involves the temporary storage and manip-
ulation of information. The memory impairments induced by
cannabis andΔ9-THC in humans aremost robust in tests of short-
term episodic and working memory (Ranganathan and D’Souza,
2006). In animal models, the effects of cannabinoids on work-
ing memory have received much attention (see Table 1), and the
data appear more congruent than in the models of long-term ref-
erence memory discussed above. Some of the procedures used to
studyworkingmemory are adapted fromprocedures used to study
acquisition of long-term memory.
Water maze
The basic water maze procedure can be modiﬁed to test working
memory by changing the location of the platform each day and
testing with only a brief delay between acquisition and a test trial.
Varvel et al. (2001) have demonstrated that Δ9-THC administered
before the testing session impairs memory in a CB1 dependent
manner without affecting locomotion.
Radial maze
The ﬁndings obtained with the working-memory version of the
water maze procedure agree with those obtained with the con-
ventional version of the radial maze, which focuses on working
memory. In rodents, systemic administration of Δ9-THC or CB1
agonists like WIN55212 or CP-55,940 increase the number of
errors (Molina-Holgado et al., 1993; Lichtman et al., 1995; Licht-
man and Martin, 1996; Mishima et al., 2001). Interestingly, Naka-
mura et al. (1991) found that Δ9-THC (given 30min before the
task) impaired performance in the test when a short delay of 5 s
was introduced between entering the fourth andﬁfth arms,but not
when the delay was longer (1 h); this suggests a more prominent
effect of Δ9-THC on working memory than on long-term refer-
ence memory. However, under a similar task Silva de Melo et al.
(2005) obtained opposite results, with systemic or intra medial
prefrontal cortex administration of THC selectively impairing
memory in the long-delay condition.
A series of experiments exploring the brain structure involved
in cannabinoid-induced impairments of working memory in the
radialmaze have shown that both the hippocampus and prefrontal
cortex are involved (Egashira et al., 2002; Silva de Melo et al.,
2005; Suenaga et al., 2008; Rubino et al., 2009; Wise et al., 2009b;
Rodrigues et al., 2011) and thatCB1 andD1–2 receptors play critical
roles (Wise et al., 2009b; Rodrigues et al., 2011).
T-maze
T-maze procedures also provide a test of spatial working mem-
ory. There are two goal arms, and rodents obtain food by entering
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the goal arm that was not entered on the previous trial. Systemic
administration of Δ9-THC (Jentsch et al., 1998; Nava et al.,
2001; Varvel et al., 2005b) or intra-hippocampal administration
of WIN55212 (Suenaga et al., 2008) impairs the performance of
and rats, and CB1 antagonists reverse these effects. Several lines
of evidence indicate the involvement of acetylcholine systems
in the effects of Δ9-THC on working memory in task such as
the T-maze and radial maze. Extracellular levels of hippocampal
acetylcholine have been shown to decrease after Δ9-THC admin-
istration (Mishima et al., 2002), and drugs that reestablish levels of
this neurotransmitter can reverse the impairing effects of Δ9-THC
(Nava et al., 2000, 2001;Mishima et al., 2002; Inui et al., 2004;Wise
et al., 2007; Egashira et al., 2008).
Delayed spatial matching
Extensive studies of working memory have been performed by
Hampton, Deadwyler, and associates, using the delayed non-
matching to position task in rats. In this task,one of two retractable
levers is extended as a sample. After the rat presses the sample
lever, the lever is retracted. After a delay period, both levers are
extended and the rat receives food or water if it presses the non-
matching lever (i.e., the one that was not presented as a sample;
Deadwyler et al., 1996; Mallet and Beninger, 1998). Many such
trials can be conducted during a daily session, with the length of
the delay varied across trials. Administration of Δ9-THC, anan-
damide, or WIN55212-2 before the session impairs performance
(Heyser et al., 1993; Mallet and Beninger, 1998; Hampson and
Deadwyler, 2000; Deadwyler et al., 2007; Goonawardena et al.,
2010; Panlilio et al., 2011). This effect is associated with a drug-
induced decrease in the ﬁring rate of hippocampal pyramidal
neurons during the initiation of the trial; preadministration of
rimonabant (IP 1.5mg/kg) reestablishes a normal level of hip-
pocampal neuronal activity and blocks the memory-impairing
effects of Δ9-THC and WIN55,212-2 (Hampson and Deadwyler,
2000; Goonawardena et al., 2010). Under some conditions, the
administration of a higher concentration (IP, 2mg/mL) of rimon-
abant alone can enhance performance in this working-memory
task (Deadwyler and Hampson, 2008). However, this result has
not been reported consistently by the Deadwyler lab and was
not obtained with the same dose of rimonabant in a study by
Mallet andBeninger (1998). Possibly, the enhancing effect is some-
times prevented by ceiling effects and requiresmodiﬁcations of the
procedure (e.g., longer delay periods) to be observed.
ENHANCED ANANDAMIDE SIGNALING AND PPAR-α ACTIVATION
Compounds that inhibit the activity of the fatty acid amide hydro-
lase enzyme (FAAH) prevent the degradation of endocannabi-
noid anandamide and thereby magnify and prolong anandamide’s
actions (Kathuria et al., 2003). FAAH inhibition also increases lev-
els of several other fatty acids – oleoylethanolamide (OEA) and
palmitoylethanolamide (PEA) – that constitute endocannabinoid-
like systems in the brain (Fegley et al., 2005). OEA and PEA do not
bind to cannabinoid receptors, but are ligands for alpha-type per-
oxisomeproliferator-activated nuclear receptors (PPAR-α). PPAR-
α is well known to be involved in a number of physiological
processes, but is just beginning to received attention for having
cognitive and other behavioral effects (Mazzola et al., 2009; Melis
et al., 2010; Mascia et al., 2011).
Surprisingly, given the preponderance of ﬁndings that cannabi-
noid agonists impair memory and the fact that FAAH inhibitors
increase levels of the endogenous cannabinoid agonist anan-
damide, FAAH inhibitors have been found to enhance learning
in several procedures. The FAAH inhibitor OL-135 (30mg/kg)
enhanced the acquisition rate in a working-memory version of
the water maze test or in the conventional ﬁxed-platform test in
(Varvel et al., 2007); however, the same dose of OL-135 did not
have such effects in an earlier study (Varvel et al., 2006). Another
FAAH inhibitor, URB597 (0.1–1mg/kg), enhanced the acquisi-
tion of passive-avoidance learning, but was not found to affect
consolidation or retrieval (Mazzola et al., 2009). In genetically
modiﬁed FAAH-compromised mice, acquisition was enhanced
in the working-memory water maze test, but not in the con-
ventional, ﬁxed-platform of test (Varvel et al., 2007; Wise et al.,
2009a).
Although both Varvel et al. (2007) and Mazzola et al. (2009)
found that rimonabant (1mg/kg in rats; 3mg/kg in mice) was
able to block the facilitating effects of FAAH inhibition onmemory
acquisition, suggesting mediation by CB1 receptors, there is evi-
dence that non-cannabinoid effects of FAAH inhibition also can
enhance learning and memory. Mazzola et al. (2009) found that
the enhancing effects of FAAH inhibition on passive-avoidance
learning could be blocked not only by rimonabant but by the
PPAR-α antagonist MK886. This suggests that FAAH inhibition
might enhance memory by increasing the levels of the endogenous
PPAR-α ligands OEA and PEA. Consistent with this hypothe-
sis, the PPAR-α agonist WY14643 produced effects similar to
those of the FAAH inhibitor URB597 on acquisition of passive-
avoidance test, and this effect of WY14643 was also blocked by
the PPAR-α antagonist MK886. In both a passive avoidance and
a ﬁxed-platform water maze procedure in rats, administration of
exogenous OEA enhanced memory (Campolongo et al., 2009a).
However, it should be noted that in the study where the FAAH
inhibitor OL-135 did not enhance water maze learning (Varvel
et al., 2006), OEA (50mg/kg) and PEA (50mg/kg) also failed to
affect working memory in the water maze. In addition,while Maz-
zola et al. (2009) found that FAAH inhibition or administration
of the PPAR-α agonist WY14643 speciﬁcally affected acquisition
of passive avoidance, Campolongo et al. (2009a) found that OEA
had effects when given immediately post-training, indicating an
effect on consolidation.
The ﬁnding that FAAH inhibition has memory effects oppo-
site to those of cannabinoid agonists might be at least partially
explained by differences in the brain areas affected by these two
kinds of treatment. As mentioned above, systemic injection of a
drug such as Δ9-THC affects CB1 receptors throughout the brain.
Systemic injection of a FAAH inhibitor selectively increasing anan-
damide levels in areas where it is being released. It is likely that
different brain areas subserve different mnemonic processes; for
example, endocannabinoid signaling in the hippocampus might
be more involved in acquisition, while endocannabinoid signal-
ing in the amygdala might be more involved in consolidation and
forgetting (Riedel and Davies, 2005).
EXTINCTION AND FORGETTING
While the fact that exogenous cannabinoids impair memory has
been studied in humans and animals for decades, it has only
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recently been recognized that endocannabinoid systems might be
involved in extinction learning. Extinction learning refers to the
cessation of a learned response when the conditions that induced
the learning no longer hold. For example, after the initial exposure
to shock in contextual fear conditioning, the conditioned freezing
responsewill gradually decrease if the subject is repeatedly exposed
to the context but no longer shocked. This loss of the learned
response might be described as forgetting, or as the establishment
of new learning appropriate to the current situation.
Using fear conditioning with a discrete cue, Marsicano et al.
(2002) were the ﬁrst to report compromised extinction learning
in CB1-knockout mice and in wild type mice given rimona-
bant (3mg/kg). Interestingly, the behavioral patterns observed
in CB1-knockout and rimonabant-treated mice were associated
with decreased long-term depression of neurons in the amygdala,
a structure known to play a critical role in extinction learning
(Quirk and Mueller, 2008). Moreover, presentation of the shock-
associated tone during extinctionwas followedby increased release
of anandamide in the basolateral amygdala of wild type mice, sug-
gesting the involvementof endocannabinoidneurotransmission in
extinction learning (Marsicano et al., 2002). It has been proposed
that endocannabinoids modulate fear-related extinction learning
by regulating the activity of kinases and phosphatases in regions
involved in fear and memory processing (Cannich et al., 2004).
The impairing effects of genetic and pharmacological block-
ade of CB1 receptors on extinction learning, but not on the
acquisition of long-term and short-term fear-related memory, has
been replicated in many laboratories with rats and mice (Suzuki
et al., 2004; Chhatwal et al., 2005; Kamprath et al., 2006; Niyuhire
et al., 2007; Pamplona et al., 2008). Also consistent with the
hypothesis that CB1 dependent mechanisms modulate extinction
learning, activation of CB1 receptors has been shown to facili-
tate fear conditioning, producing effects opposite to those of CB1
antagonists. Administration of the anandamide uptake inhibitor
AM404 (IP: 10mg/kg; 1.0μg/μL, i.c.v.) during extinction train-
ing facilitated the extinction of startle or freezing elicited by a
shock-associated context (Chhatwal et al., 2005; Bitencourt et al.,
2008; Pamplona et al., 2008); this effect was CB1 dependent,
since it is blocked by a dose of rimonabant that was ineffective
by itself (Bitencourt et al., 2008). Low doses (0.25mg/kg, IP)
but not a high dose (5mg/kg) of the CB1 agonist WIN55,212-2
impaired contextual fear conditioning under the same conditions
where rimonabant enhanced it (Chhatwal et al., 2005; Pamplona
and Takahashi, 2006). Moreover Ganon-Elazar and Akirav (2009)
have shown that micro-injection of a low dose of WIN55,212-
2 in the basolateral amygdala has no effect by itself but can
reverse the disrupting effect of a stressor on extinction of passive
avoidance.
The effects of cannabinoid compounds on extinction learn-
ing have also been conﬁrmed with another aversively motivated
test, the water maze. In this test, Varvel et al. (2005b, 2007) found
that rimonabant (3mg/kg) treatment or genetic CB1 disruption
impaired extinction learning, but THC did not affect extinction
(Varvel et al., 2007). Surprisingly, pharmacological and genetic
manipulations of CB1 have not been found to affect extinction
learning in tasks based on appetitive conditioning (Hölter et al.,
2005; Niyuhire et al., 2007; Harloe et al., 2008).
It has been suggested that the effects of CB1 antagonism in
extinction procedures may depend on perseverance. For example,
rimonabant-treated or CB1-knockout mice show deﬁcits in learn-
ingwhen the platform ismoved to a new location in thewatermaze
test (Varvel and Lichtman, 2002; Pamplona et al., 2006). However
this view is not supported by another study in which certain doses
of CB1 agonists and antagonists facilitated or impaired, respec-
tively, ﬂexibility between different strategies (Hill et al., 2006). In
this experiment, separate groups of rats were trained to use either
a visual cue or a spatial (left vs. right) strategy to locate food
in one arm of a plus-maze. Flexibility was then measured as the
number of perseverative errors when the opposite strategy was
required. Administration of the CB1 antagonist AM251 (2mg/kg)
20min before testing reduced perseverative errors, whereas the
CB1 agonist HU-210 (20μg/kg, IP) increased them.
The effects of FAAH inhibition on extinction learning have
also been studied. FAAH null mice and mice treated with the
FAAH inhibitor OL-135 show enhanced extinction learning in the
water maze test (Varvel et al., 2007). Therefore FAAH inhibitors
have unique effects among the endocannabinoid-related com-
pounds, facilitating both acquisition and extinction processes.
This characteristic may be due, as previously mentioned, to
the ability of FAAH inhibitors to increase not only brain lev-
els of anandamide but also of PEA and OEA. Indeed it has
been shown that OEA administration (30mg/kg) can facilitate
extinction of passive avoidance in rats (Murillo-Rodríguez et al.,
2001).
CONCLUSION – ENDOCANNABINOID SIGNALING AND COGNITION
Most of the evidence indicates that activating the endocannabi-
noid system interferes with situation-dependent working memory
and the acquisition of long-term memory (see Table 1). Inhibit-
ing the endocannabinoid system, on the other hand, can enhance
learning and memory. Surprisingly, increasing endogenous levels
of anandamide and facilitating endocannabinoid signaling with a
FAAH inhibitor can enhance learning; but, this probably occurs
through the endocannabinoid-relatedPPAR-α systemand the fatty
acids OEA and PEA. There is accumulating evidence that the
endocannabinoid system plays a special role in extinction learn-
ing related to aversive conditioning. This role, along with its role
in emotion, suggests cannabinoid-related medications might be
developed for treating phobias.
EFFECTS OF ENDOCANNABINOID SYSTEM MODULATION ON
EMOTIONAL BEHAVIOR
The effects of cannabinoid agonists and antagonists on emotional
behavior have recently been reviewed elsewhere (Bambico et al.,
2009; Moreira andWotjak, 2010) and will only be discussed brieﬂy
here. Instead, we will focus on studies that involve genetic disrup-
tion of CB1 receptors or genetic or pharmacological manipulation
of the anandamide-degrading enzyme FAAH. Thesemethods gen-
erally provide more direct information about endocannabinoid
function because they exclude or enhance cannabinoid signaling,
rather than directly stimulating cannabinoid receptors.
The animal models of anxiety that have been used with these
endocannabinoid manipulations generally measure changes in
rodents’ tendency to avoid certain inherently aversive situations;
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increased avoidance implies increased anxiety (an anxiogenic
effect), and decreased avoidance indicates decreased anxiety (an
anxiolytic effect). The avoided situations include brightly lit
areas (light/dark test), open areas (open ﬁeld test), open elevated
areas (elevated plus-maze and O-maze tests), social interaction
with unfamiliar conspeciﬁcs (social interaction test), and pain-
associated stimuli (Vogel conﬂict test, shock prod burying test).
In most of these tests, locomotor activity can also be moni-
tored to assess the possibility that a drug or dose is causing
non-speciﬁc sedation or motor depression, rather than affecting
emotional behavior. Animal tests of depression generally model
speciﬁc depression-like symptoms. For example, some tests mea-
sure changes in rodents’ tendency to eventually becoming immo-
bile when it is not possible to escape from water (forced swim test)
or being suspended by the tail (tail suspension test). A decrease
in the duration of immobility is considered an antidepressant-
like effect and an increase in duration a depressant-like effect.
Increased immobility is believed to be a sign of “behavioral
despair” that putatively models the depression symptoms “loss of
energy” and/or “feelings of hopelessness.” A depression-like state
can be induced in laboratory rodents by exposing them tomild but
recurrent and unpredictable stressors (chronic mild stress model).
In this model, a decrease in consumption of sucrose is believed to
model anhedonia (loss of pleasure) another important symptom
of depression in humans.
EFFECTS OF CB1 RECEPTOR AGONISTS AND ANTAGONISTS ON
EMOTIONAL BEHAVIOR
Cannabinoid receptor agonists decrease depression-like behaviors
in a variety of species and models (Bambico et al., 2009). For
example, in the forced swim test the CB1 agonists anandamide,
Δ9-THC,CP-55,940,HU-210, andWIN55,212-2 decrease immo-
bility in the forced swim paradigm in BALB/C and CD1 mice and
in Long–Evans, Sprague-Dawley, and Wistar rats, effects that are
blocked by theCB1 antagonists rimonabant andAM251.Although
these ﬁndings suggest that cannabinoid receptor agonists hold
promise as targets for the treatment of depression, these drugs have
signiﬁcant side effects (e.g., psychosis and panic) that preclude
their clinical use (Moreira et al., 2009). Similarly, CB1 antagonists
also been found to have both therapeutic potential and unac-
ceptable side effects; the antagonist rimonabant, which showed
promise as a treatment for obesity, was recalled from the market
because of emotional, depression-like side effects.
The effects of cannabinoid agonists are somewhat more com-
plex in animal models of anxiety than in animal models of
depression.High and lowdoses of cannabinoid agonists often have
opposite effects (Moreira andWotjak, 2010),with lowdoses induc-
ing anxiolytic effects, while high doses induce anxiogenic effects.
Both effects can be inhibited by CB1 antagonists, although para-
doxical agonist/antagonist interactions have also been reported
(Haller et al., 2007).
Caveats
Discrepant ﬁndings with CB1 receptor ligands are usually attrib-
uted to differences in dosage and treatment duration, experimen-
tal conditions, and species (Bambico et al., 2009; Moreira and
Wotjak, 2010). However, these factors have rarely been studied
systematically, and the reasons for discrepant ﬁndings are actually
poorly understood. One possible explanation lies in the fact that
CB1 receptors are expressed on both glutamatergic andGABAergic
synapses and these neurotransmitter systems often have oppo-
site effects on emotions, especially on anxiety. We have shown
that the relative cannabinoid sensitivity of GABA and glutamate
neurotransmission differs between CD1 and Wistar rats and that
these differences are likely responsible for the differential effects of
cannabinoids on anxiety in these two species (Haller et al., 2007).
Similar differences in cannabinoid function might be present in
different strains of the same species, or even individual sub-
jects. Thus, discrepant ﬁndings could be due to differences in
the expression, distribution, and functional characteristics of CB1
receptors.
GENETIC DELETION OF CB1 RECEPTORS
The impact of genetic deletion of CB1 in animal models of anx-
iety and depression was demonstrated in three studies published
in 2002 (see Table 2). Maccarrone et al. (2002) showed that CB1-
knockout mice were more anxious than wild type in the open
ﬁeld and light/dark tests; however, this effect was present in young
mice but not in 4-month-old mice. Martin et al. (2002) reported
that deletion of the CB1 gene induced signs of anxiety in the
light/dark test and depression-like symptoms in the sucrose con-
sumption test after chronic mild stress. Finally, Haller et al. (2002)
showed that CB1-knockout mice robustly express anxiety in the
elevated plus-maze, but this kind of effect was not induced by
the CB1 antagonist rimonabant in wildtype mice. A later study by
the same group found that, unlike rimonabant but like CB1 dele-
tion, the CB1 antagonist AM251 did increase anxiety (Haller et al.,
2004b). Subsequent studies have also replicated the depression-
like phenotype of CB1-knockout mice in the forced swim test
(Fride et al., 2005), but others have not (Steiner et al., 2008a,b).
Conditional mutants lacking CB1 receptors at their cortical glu-
tamatergic neurons showed decreased immobility in the forced
swim test, suggesting an antidepressant effect of this more targeted
genetic manipulation (Steiner et al., 2008b).
Like the depressant effects, the anxiogenic effects of CB1 dele-
tion have been replicated in a number of studies using a variety
of procedures (see Table 2). These include the elevated plus-maze,
social interaction, and light/dark tests (Urigüen et al., 2004;Mikics
et al., 2009; Hill et al., 2011). In other cases, however, the effect was
weak. For example, risk assessment was decreased in the elevated
plus-maze,but open armexploration (themainmeasure of anxiety
in this test) was not affected (Jacob et al., 2009). Also,mutant mice
lacking the CB1 receptor at their glutamatergic synapses showed
no changes in anxiety (Jacob et al., 2009). The effects of gene
disruption were also weak in the mouse defense test battery, a
less commonly used but behaviorally valid model of anxiety that
measures responses to an unconditioned predator-related stim-
ulus (Griebel et al., 2005). In one study, the anxiolytic effects of
ethanolwerenot diminished inCB1-knockout in the elevatedplus-
maze (Houchi et al., 2005). In another experiment that used the
shock prod burying test, CB1 deletion itself had anxiolytic effects
(Degroot and Nomikos, 2004).
Some of the inconsistency in the effects of CB1 on anxiety-
and depression-like behavior might be due to changes in
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Table 2 | Summary of studies investigating anxiety-like and depression-like behavior in knockout with cannabinoid CB1 with deleted.
Authors Animals Test Anxiety Depression
Maccarrone et al. (2002) CB1 KO adolescents (CD1) Open ﬁeld (bright light) ↑
Maccarrone et al. (2002) CB1 KO adults (CD1) Open ﬁeld (bright light) =
Maccarrone et al. (2002) CB1 KO adolescents (CD1) Light–dark test ↑
Maccarrone et al. (2002) CB1 KO adults (CD1) Light–dark test
Martin et al. (2002) CB1 KO (CD1) Light–dark test ↑
Martin et al. (2002) CB1 KO (CD1) Active avoidance ↑
Haller et al. (2002) CB1 KO (CD1) EPM ↑
Fride et al. (2005) CB1 KO (C57BL/6J) Forced swim test ↑
Steiner et al. (2008a) CB1 KO (C57BL) Forced swim test =
Steiner et al. (2008b) Glu-CB1 KO (C57BL/6N) Forced swim test ↓
Steiner et al. (2008b) CaMK-CB1 KO (C57BL/6N) Forced swim test =
Steiner et al. (2008b) GABA-CB1 KO (C57BL/6N) Forced swim test =
Jacob et al. (2009) CB1 KO (C57BL/6N) Light–dark test (high illumination) ↑
Jacob et al. (2009) CB1 KO (C57BL/6N) EPM ↑
Jacob et al. (2009) Glu-CB1 KO (C57BL/6N) Light–dark test =
Jacob et al. (2009) Glu-CB1 KO (C57BL/6N) EPM =
Griebel et al. (2005) CB1 KO (C57BL) Mouse defense test battery =
Houchi et al. (2005) CB1 KO (CD1) EPM =
Houchi et al. (2005) CB1 KO (CD1) treated with 1.5mg/kg
ethanol, IP
EPM KO=WT
Degroot and Nomikos (2004) CB1 KO (C57BL/6J) Shock-probe burying test ↑(under some parameters)
Haller et al. (2004a) CB1 KO (CD1) EPM (high illumination) ↑
Hill et al. (2011) CB1 KO (ICR) EPM ↑
EPM, elevated plus-maze; KO, knockout;WT, wild type. For effects in models of anxiety and depression, ↓ indicates impairment; ↑ indicates enhancement;= indicates
no effect.
responsiveness to environmental stimuli. In a recent study, Jacob
et al. (2009) showed that behavioral differences between wild type
and CB1-knockout mice were strongly inﬂuenced by the level of
illumination under which the test was performed; in models of
anxiety, such as the open ﬁeld and the elevated plus-maze the
behavior of CB1-knockout differed markedly depending on light
intensity. The impact of light intensity was also studied by Haller
et al. (2004a), who reported that the anxiogenic effects of CB1
gene disruption are evident when mice are tested in light, but
not when they are tested in darkness. The same study suggested
that the impact of CB1 gene deletion on social behaviors depends
on the level of familiarity with the testing environment; opposite
effects were obtained in the home-cage and in an unfamiliar cage.
Even the study where CB1 deletion had an anxiolytic effect (Deg-
root and Nomikos, 2004) can be perceived as a particular case of
the interaction between environmental stimuli and CB1-knockout
behavior, as the shock prod burying test examines the immediate
behavioral response to electric shocks.
Taken together, these ﬁndings suggest that deletion of endoge-
nous CB1 signaling generally produces an anxious phenotype,
but this effect is strongly dependent on environmental condi-
tions. Intriguingly, Hill et al. (2011) recently demonstrated that
the behavioral and neural changes associated with CB1 gene dis-
ruption are very similar to those seen in chronically stressed wild
type mice. This suggests that CB1 deletion produces a chronic
stress state that might contribute to altered responsiveness to
environmental stimuli.
ENHANCEMENT OF ANANDAMIDE SIGNALING THROUGH INHIBITION
OF FAAH
The ﬁrst study demonstrating the impact of FAAH inhibitors on
emotional behavior was published by Kathuria et al. (2003). They
showed that the FAAH inhibitor URB597 robustly increases brain
levels of anandamide but not 2-AG, and it has the anxiolytic
effects of decreasing pup ultrasonic vocalizations and promot-
ing exploration of the open section of the elevated O-maze. The
authors concluded that their “results indicate that anandamide
participates in the modulation of emotional states and point to
fatty acid amide hydrolase inhibition as an innovative approach to
anti-anxiety therapy.” In a later publication, an overlapping group
of authors demonstrated that URB597 decreases depression-like
behaviors in both the forced swim and tail suspension models
of depression, ﬁndings that “support a role for anandamide in
mood regulation and point to fatty acid amide hydrolase as a pre-
viously uncharacterized target for antidepressant drugs” (Gobbi
et al., 2005). Piomelli et al. (2006) concluded that URB597 does
not evoke classical cannabinoid-like effects, but enhances the tonic
actions of anandamide on a subset of CB1 receptors that are nor-
mally engaged in controlling emotion and pain. As such, FAAH
inhibition in general and URB597 in particular show promise as
treatments for anxiety and depression.
Effects of FAAH inhibition in models of depression
These early publications on the antidepressant- and anxiolytic-
like effects of FAAH inhibition were supported by a series of
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Table 3 | Summary of studies investigating the effects of the FAAH inhibitor URB597 or genetic deletion of FAAH on anxiety-like and
depression-like behavior in rodents.
Authors Animals Drug Doses and route Test Anxiety Depression
Kathuria et al. (2003) Sprague-Dawley rats URB597 0.1mg/kg, IP Elevated 0 maze ↓
Kathuria et al. (2003) Sprague-Dawley rats
(pups)
URB597 0.1mg/kg, IP Isolation induced
USVs
↓
Gobbi et al. (2005) Sprague-Dawley rats URB597 0.1mg/kg, IP Tail suspension test ↓
Gobbi et al. (2005) Sprague-Dawley rats URB597 0.1mg/kg, IP Forced swim test ↓
Gobbi et al. (2005) Sprague-Dawley rats URB597 0.1mg/kg, IP (repeated
4 days)
Forced swim test ↓
Adamczyk et al. (2008) Wistar rats URB597 0.1–0.3mg/kg, IP Forced swim test ↓
Bambico et al. (2010) FAAH KO mice
(C57BL6/6J)
N/A N/A Tail suspension test ↓
Bambico et al. (2010) Mice, FAAH KO
(C57BL6/6J)
N/A N/A Forced swim test ↓
Bortolato et al. (2007) Wistar rats URB597 0.3mg/kg IP (repeated
5weeks)
Sucrose
consumption after
chronic mild stress
↓
Hill et al. (2007) Long–Evans rats
(ovariectomized
female+estradiol
treatment)
URB597 0.1mg/kg, IP Forced swim test ↓
Realini et al. (2011) Sprague-Dawley rats
(females+10days
THC treatment)
URB597 0.3mg/kg IP (repeated
30 days)
Forced swim test ↓
Realini et al. (2011) Sprague-Dawley rats
(females+10days
THC treatment)
URB597 0.3mg/kg, IP (repeated
30 days)
Sucrose
consumption
↓
Wright et al. (2010) Sprague-Dawley rats
(DFP treated)
URB597 3mg/kg, IP Forced swim test =
McLaughlin et al. (2007) Sprague-Dawley rats URB597 0.5 and 1μg (hippo
campus)
Forced swim test =
Manna and Jain (2011) Swiss mice URB597 0.05–10μg/mouse, ICV Forced swim test ↓
Moise et al. (2008) Syrian hamsters URB597 0.1–0.3mg/kg, IP EPM ↓
Moise et al. (2008) Syrian hamsters URB597 0.3–3mg/kg, IP Conditioned and
unconditioned social
defeat test
=
Moreira et al. (2008) C57BL/6N mice URB597 10mg/kg, IP EPM ↓
Patel and Hillard (2006) ICR mice URB597 0.1–0.3mg/kg, IP EPM ↓
Lisboa et al. (2008) Wistar rats URB597 0.01 nmol, IC (dorsal
periaqueductal gray)
Vogel conﬂict test ↓
Rubino et al. (2008) Sprague-Dawley rats URB597 0.1μg/rat EPM ↓
Scherma et al. (2008) Sprague-Dawley rats URB597 0.1–0.3mg/kg, IP Light–dark test ↓
Naderi et al. (2008) NMRI mice AM404 1–2mg/kg, IP EPM ↓
Naderi et al. (2008) NMRI mice URB597 0.03–0.3mg/kg, IP EPM =
Micale et al. (2009) C57BL/6J mice URB597 1mg/kg, IP EPM ↓
Micale et al. (2009) C57BL/6J mice URB597 0.1–0.5mg/kg, IP EPM =
Naidu et al. (2007) C57BL/6J-ICR mice URB597 0.3–1–3mg/kg, IP EPM =
Naidu et al. (2007) C57BL/6J-ICR mice URB597 10mg/kg, IP EPM =
Naidu et al. (2007) C57BL/6J-ICR mice URB597 0.1mg/kg, IP Modiﬁed EPM ↓
Naidu et al. (2007) FAAH KO mice
(C57BL/6J)
N/A N/A EPM =
Naidu et al. (2007) FAAH KO mice
(C57BL/6J)
N/A N/A Tail suspension test =
Naidu et al. (2007) C57BL/6J mice URB597 0.1–10mg/kg, IP Tail suspension test =
(Continued)
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Table 3 | Continued
Authors Animals Drug Doses and route Test Anxiety Depression
Naidu et al. (2007) FAAH KO mice
(C57BL/6J)
N/A N/A Modiﬁed tail
suspension test
↓
Naidu et al. (2007) C57BL/6J mice URB597 0.1mg/kg, IP Modiﬁed tail
suspension test
↓
Seillier and Giuffrida (2011) Wistar rats URB597 0.1, 0.3, 1mg/kg, IP EPM =
Haller et al. (2009) Sprague-Dawley rats URB597 0.1–0.3mg/kg, IP EPM (low
aversiveness)
=
Haller et al. (2009) Sprague-Dawley rats URB597 0.1–0.3mg/kg, IP EPM (high
aversiveness)
↓
EPM, elevated plus-maze. For effects in models of anxiety and depression, ↓ indicates impairment; ↑ indicates enhancement;= indicates no effect.
subsequent ﬁndings (see Table 3). In models of depression, sys-
temic, and i.c.v. treatments with URB597, as well as genetic
deletion of FAAH, decreased immobility in the forced swim,
and tail suspension tests (Adamczyk et al., 2008; Bambico et al.,
2010; Manna and Jain, 2011; Umathe et al., 2011), while systemic
URB597 administration counteracted the deleterious effects of
chronic mild stress (Bortolato et al., 2007), abolished estrogen
deﬁciency-induced depression in female rats (Hill et al., 2007), and
reversed depression-like symptoms induced by THC in adolescent
female rats (Realini et al., 2011). In the forced swim test, URB597
reversed depression-like effects in rats 29 days (but not 8 days)
after exposure to diisopropylﬂuorophosphate (Wright et al., 2010).
The CB1 dependence of these effects was veriﬁed in most of the
cited studies, conﬁrming that they were due to FAAH-induced
enhancement of anandamide signaling at CB1 receptors. The role
of anandamide in these antidepressant effects is further supported
by the ﬁnding that the anandamide-transport inhibitor AM404
exerted similar effects in some studies (Adamczyk et al., 2008;
Umathe et al., 2011).
However, conﬂicting ﬁndings also exist. URB597 had no effect
when infused into the dentate gyrus of the hippocampus, despite
the fact that the direct CB1 agonist HU-210 administered in the
same way produced antidepressant effects in the forced swim test
(McLaughlin et al., 2007). This ﬁnding suggests that depression-
like behavior is affected by anandamide-independent cannabinoid
mechanisms in certain cases and in certain brain areas. Naidu
et al. (2007) found that the FAAH inhibitors URB597 and OL-135
only affected depression-like behavior in the forced swim and tail
suspension tests when the tests were performed under modiﬁed
lighting conditions and when large sample sizes were used.
Effects of FAAH inhibition in models of anxiety
URB597 decreased anxiety in the elevated plus-maze when given
systemically (Patel and Hillard, 2006; Moise et al., 2008; Moreira
et al., 2008) or when injected into the medial prefrontal cortex
or dorsolateral periaqueductal gray, two regions that play impor-
tant roles in the control of anxiety (Lisboa et al., 2008; Rubino
et al., 2008).URB597 also abolished the anxiogenic response
measured in the elevated plus-maze during withdrawal after an
acute administration of alcohol (Cippitelli et al., 2008). Anxi-
olytic effects of URB597 were also shown in the Vogel conﬂict
test (injected into dorsolateral periaqueductal gray; Lisboa et al.,
2008) and light–dark test (injected systemically; Scherma et al.,
2008). Like FAAH inhibition, anandamide-transport inhibition
decreased anxiety (Lisboa et al., 2008; Naderi et al., 2008), sug-
gesting that the enhancement of endogenous anandamide release
decreases anxiety irrespective of the method by which it was
achieved. Mice with FAAH genetically deleted showed reduced
emotionality in both the social interaction test and the open
ﬁeld test, and these differences were abolished by treatment with
rimonabant (Cassano et al., 2011).
However, there are also a number of conﬂicting ﬁndings regard-
ing the effects of FAAH inhibition on anxiety (see Table 3). Some
of these contradictions can be considered negligible. For exam-
ple, acute or chronic treatment with URB597 doses that were very
effective at producing anxiolytic effects in other studies (0.1, and
0.5mg/kg) did not affect anxiety in the elevated plus-maze in the
study by Micale et al. (2009), but a higher dose (1mg/kg) did.
In another study, URB597 had no effect on anxiety in the mouse
defense test battery, but had an anxiolytic effect in a more con-
ventional model, the elevated plus-maze (Moise et al., 2008). To
a certain extent, the ﬁndings by Scherma et al. (2008) are also at
variancewith the assumption that enhanced anandamide signaling
decreases anxiety. Although these authors did show an anxiolytic
effect with URB597, co-administration of anandamide reversed
this effect. This ﬁnding might be explained by the fact that FAAH
inhibition selectively affects areas where endogenous anandamide
is being released, while exogenous administration of anandamide
(the effects of which are prolonged by FAAH inhibition) would
affect cannabinoid receptors throughout the brain.
Harder to explain are the ﬁndings of Naderi et al. (2008),Naidu
et al. (2007), and Seillier and Giuffrida (2011), who failed to detect
any anxiolytic effect of URB597 in the elevated plus-maze (i.e.,
the test in which FAAH inhibition was ﬁrst found to be anxi-
olytic). Haller et al. (2009) reported that URB597 did not decrease
anxiety when the elevated plus-maze test was performed under
mildly aversive conditions (e.g., in a familiar room or under low
light). In contrast, the benzodiazepine anxiolytic chlordiazepoxide
decreased anxiety under all conditions. In the case of genetic dele-
tion of FAAH, mutant mice showed evidence of decreased anxiety
relative to wild type mice under both bright and dim lighting con-
ditions in the social interaction and open ﬁeld tests; but, when the
mutant mice received rimonabant under dim lighting conditions
in the open ﬁeld test (i.e., under less aversive conditions), their
behavior suggested hypersensitivity to anxiogenic effects of CB1
blockade (Cassano et al., 2011).After carefully reviewingpublished
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methodological details and personally interviewing the authors of
earlier publications, Haller et al. (2009) suggested that success or
failure in detecting anxiolytic effects with URB597 was largely
explained by the degree of aversiveness of the testing environment
in particular studies. Since various testing conditions can differ-
entially model speciﬁc forms of anxiety, these ﬁndings suggest
that FAAH inhibition (and its functional equivalent, anandamide-
transport inhibition)might blunt the anxiogenic effects of stressful
environmental stimuli rather than producing an overall reduction
in anxiety.
CONCLUSION – ENDOCANNABINOID SIGNALING AND EMOTIONAL
BEHAVIOR
Cannabinoid signaling appears to decrease depression-like and
anxiety-like behaviors in laboratory models. These effects were
observed using a variety of means to affect cannabinoid signaling,
a variety of animalmodels, and a variety of species. The reasons for
discrepancies are multiple, but an increasing number of publica-
tions suggest that the emotional effects of enhanced endocannabi-
noid signaling largely depend on environmental inﬂuences. These
ﬁndings suggest that the anxiolytic effects, and possibly the antide-
pressant effects, of endocannabinoid signaling are enhanced under
aversive conditions, which strengthens, rather than weakens, the
putative usefulness of medications that enhance endocannabinoid
signaling in the treatment of emotional disorders.
CONTEXT DEPENDENCE OF ENDOCANNABINOID
MODULATION OF COGNITIVE AND EMOTIONAL BEHAVIOR
BRAIN FUNCTIONS AND ASSUMPTIONS FOR BEHAVIOR
Uniquely, endocannabinoids signal “backward”: they are released
from the post-synaptic membrane and inhibit the synaptic
neurotransmission that triggered their release (Wilson and Nicoll,
2001). Although a certain, probably low, level of tonic activation
cannot be excluded, the endocannabinoid signal occurs phasi-
cally on demand, i.e., when the intensity of anterograde synaptic
communication reaches certain levels (Di Marzo et al., 1999; Mar-
sicano et al., 2003; Lutz, 2004; Adermark and Lovinger, 2007).
As such, the main role of endocannabinoid signaling appears to
be the blockade of excessive neuronal activation. The CB1 recep-
tor is strongly expressed in limbic structures (Herkenham et al.,
1991), suggesting that cannabinoid signaling has a particularly
important role in the control of neuronal responses induced by
environmental challenges that often involve an emotional dimen-
sion. As brain anandamide levels are strongly increased by aversive
stimuli (Walker et al., 1999; Kirkham et al., 2002; Marsicano
et al., 2002; Hohmann et al., 2005), one can hypothesize that
the activity dependent release of endocannabinoids serves as a
feedback mechanism that reduces the amplitude of challenge-
induced neuronal excitations (Gerdeman and Lovinger, 2001;
Adermark and Lovinger, 2007; Straiker and Mackie, 2009). This
mechanism may be one that explains the strong impact of envi-
ronmental conditions on the behavioral consequences of FAAH
inhibition. Particularly, enhanced dampening of aversion-induced
neuronal activations may lessen the behavioral impact of aversive
stimuli.
In most cases the cognitive and emotional consequences of
FAAH inhibition have been demonstrated to be CB1-mediated.
The broad effects of anandamide signaling may offer an alterna-
tive explanation for the impact of environmental conditions on
the behavioral consequences of FAAH inhibition. CB1 receptors
occur on GABAergic and glutamatergic synapses, and activation
of these receptors can inhibit the release of several neurotransmit-
ters, including glycine, acetylcholine, norepinephrine, dopamine,
serotonin, and cholecystokinin (Gifford and Ashby, 1996; Ishac
et al., 1996; Cadogan et al., 1997; Katona et al., 1999, 2001; Nakazi
et al., 2000; Beinfeld and Connolly, 2001; Hájos and Freund, 2002;
Fernández-Ruiz et al., 2010). Thus, endocannabinoids affect the
function of many neurotransmitter systems, some of which play
opposing roles. For example, glutamatergic mechanisms appear to
promote anxiety while GABAergic mechanisms appear to inhibit
it (Millan, 2003). This diversity of cannabinoid roles and the
complexity of task-dependent activation of neuronal circuits may
inherently lead to the effects of endocannabinoid activation being
strongly dependent on environmental conditions.
Presumably, each environmental challenge and behavioral
response is bound to the activation of particular neuronal circuits.
The effects of cannabinoid signaling probably depend on the ratio,
brain location, and neurochemical nature of those neurons that
express cannabinoid receptors and are activated in the particular
situation. A small change in the environment might recruit new
neurons in the situation-dependent circuit, changing the share,
location, and neurochemical nature of the cannabinoid-controlled
synapses that were activated. Thus, each effect of cannabinoids
would be speciﬁc to the situation.
The hypothesis presented here has two parts: that cannabi-
noid signaling has an important role in dampening excessive
neuronal responses induced by environmental challenges that
often involve an emotional dimension, and that the function of
endocannabinoid neuronal circuits is situation-dependent. Endo-
cannabinoid signaling is activated when there is a relatively high
level of synaptic activity, as would be triggered by environmental
challenges that require prompt behavioral responses. Retrograde
signaling by cannabinoids would affect only those neurons that:
(1) are highly activated by the perception or interpretation of
the challenging information and by the behavioral response; and
(2) also express CB1 receptors on their axon terminals. These
conditions are likely to be met by neurons that have oppos-
ing roles overall (e.g., glutamatergic and GABAergic neurons)
or have wide ranging behavioral effects (e.g., monoaminergic
neurotransmission). As a result, cannabinoids selectively affect
a mosaic of widely heterogeneous neurons that may have con-
vergent, divergent, or independent effects on the development of
the behavioral response, and leave many neurons unaffected, or
affected only indirectly. Interfering with such a complex regula-
tory process naturally leads to complex and situation-dependent
effects. Under such conditions, the relative consistency of avail-
able ﬁndings may be due to the fact that scientiﬁc studies are
highly standardized. Even small deviations from experimental
protocols (e.g., directing the light on the tail of rats in the tail
suspension test; Naidu et al., 2007) may bring about surprising
ﬁndings. More surprising ﬁndings can be expected after more
dramatic changes in experimental conditions, for example by
varying the aversiveness of environmental conditions (Haller et al.,
2009).
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One possible argument against this hypothesis is that anan-
damide may not be directly involved in CB1-mediated retrograde
endocannabinoid signaling, because the post-synaptic localiza-
tion of its synthesizing enzymes is at variance with the pre-
synaptic localization of the CB1 receptor (Katona and Freund,
2008). One has to note, however, that cannabinoids were shown
to affect extra-synaptic (volumetric) neurotransmission (Lau and
Schloss, 2008; Morgese et al., 2009), and endocannabinoids, espe-
cially anandamide, are able to exert effects via the putative CB3
(non-CB1/non-CB2) cannabinoid receptor (De Petrocellis and Di
Marzo, 2010). One also has to note that discrepancies between
functional and morphological ﬁndings may be fairly common in
the case of cannabinoid signaling (see e.g., Kawamura et al., 2006).
CONCLUSION AND PRACTICAL IMPLICATIONS
Conﬂicting ﬁndings are not rare in behavioral pharmacology. Yet,
the enhancement or blockade of endocannabinoid signaling has
provided inconsistent ﬁndings even within the same laboratory;
moreover, deliberate changes in environmental conditions have
resulted in marked changes in the effects of the same manipula-
tions within the same series of experiments. Taken together, the
ﬁndings reviewed here raise the possibility that endocannabinoid
signaling may change the impact of environmental inﬂuences on
behavior rather than affecting one or another speciﬁc behavior.
This assumption may be especially valid for emotional behaviors,
but it may indirectly affect ﬁndings obtained in tests where emo-
tions are not the focus, such as learning and memory. Further
research in this respect appears warranted.
From a practical point of view, the assumption formulated
above may not necessarily invalidate cannabinoid neurotransmis-
sion as a pharmaceutical target. Altered responses to environ-
mental stimuli are at the core of emotional disorders, and also
appertain to disorders related to learning and memory. Thus,
the ability of cannabinoid-related treatments to modulate the
impact of challenging environmental conditions on emotional and
cognitive behavior could be a productive focus for medications
development.
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